{"id":"W2567743054","doi":"10.1016/j.jtho.2016.11.010","title":"PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Pemetrexed; Lung cancer; Internal medicine; Oncology; Chemotherapy; Quality of life (healthcare); Adverse effect; Progression-free survival; Tolerability; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002615898,0.0006858994,0.001474933,0.0003562908,0.0002669183,0.001074797,0.0008384938,0.0009725898,0.004438411],"category_scores_gemma":[0.002394692,0.0003060793,0.00308544,0.0006913893,0.0004104974,0.001366626,0.0006856063,0.00258487,0.0007060738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00115976,"about_ca_system_score_gemma":0.0009198586,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002032047,"about_ca_topic_score_gemma":0.004009486,"domain_scores_codex":[0.9990722,0.0003583927,0.00008120957,0.0001950474,0.000128251,0.000164879],"domain_scores_gemma":[0.9983891,0.0005571982,0.0005052484,0.00009052266,0.00007393982,0.000384088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8531246,0.002820791,0.06174061,0.001080358,0.009693279,0.0001018664,0.00008789237,0.002836845,0.00297715,0.0002877837,0.009875288,0.05537363],"study_design_scores_gemma":[0.2548527,0.1153353,0.5949447,0.0005035341,0.0151233,0.0003535193,0.0002824136,0.00441561,0.002670836,0.0009959737,0.01033984,0.0001822549],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719876,0.007444804,0.0003211861,0.001150195,0.0002704565,0.0003436246,0.01512375,0.00005811069,0.003300354],"genre_scores_gemma":[0.979182,0.001822822,0.0004996731,0.0009177116,0.0002050955,0.0006049574,0.01477086,0.00002381602,0.001972995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004438411,"threshold_uncertainty_score":0.01484793,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09413103862692979,"score_gpt":0.4769493827011173,"score_spread":0.3828183440741875,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}